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Flexible Initial Dosing of Atorvastatin Based Upon Initial 
Low-Density Lipoprotein Cholesterol Levels in Type 2 
Diabetic Patients
Atorvastatin  Study  Group  in  Korea
Background/Aims  :  We  used  flexible  starting  doses  and  early  titration  of  atorvastatin  to  determine  the  rate  of 
achievement of a low-density lipoprotein cholesterol (LDL-C) target for hyperlipidemic patients with type 2 diabetes mellitus. 
Methods : This study was a multicenter, open-label, prospective trial of atorvastatin therapy in hyperlipidemic patients 
with type 2 diabetes. The patients were divided into three groups according to initial LDL-C levels (130-149, 150-159 
and≥160 mg/dL) , and 10, 20, and 40 mg of  atorvastatin was administered to each group, respectively. If LDL-C did 
not reach the 100 mg/dL target level at four weeks after initiation of treatment, the doses were increased by one step. 
Endothelial  function  tests  and  plasminogen  activator  inhibitor  (PAI)-1  levels  were  measured  in  41  patients. 
Results : Groups  of  62, 18, and 69 patients were started on 10, 20, and 40 mg of atorvastatin, respectively, and 
91%  of  the  patients  achieved  the  LDL-C  target  after  four  weeks  of  treatment.  The  overall  percentage  of  patients 
achieving  the  LDL-C  target  after  eight  weeks  of  treatment  was  89.3%:  87.5% in  the  10  mg group,  86.4%  in  the 20 
mg group, 93.9% in the 40 mg group, and 66.7% in the 80 mg group. A statistically significant reduction was observed 
in  the  mean  percentage  change  in  flow-mediated  endothelium-dependent  dilatation  after  eight  weeks  of  treatment 
(p<0.0001). 
Conclusions  :  Flexible  initial  dosing  and  early  aggressive  titration  of  atorvastatin  according  to  LDL-C  levels  is  an 
efficient  and  safe  strategy  for  achieving  the  target  level  and  for  improving  endothelial  dysfunction  in  hyperlipidemic 
patients  with  type  2  diabetes.
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INTRODUCTION
The  development  of  type  2  diabetes  mellitus  (T2DM)  is 
accompanied  by  multiple  risk  factors  for  developing  coronary 
heart  disease  (CHD),  such  as  hypertension,  obesity,  and 
dyslipidemia.  Among  modifiable  risk  factors,  the  association 
between  plasma  low-density  lipoprotein  cholesterol  (LDL-C)  and 
CHD risk is well established, and this association holds true for 
individuals  with  diabetes  even  at  low  plasma  LDL-C  concentra-
tions
1-3).  Based  on  several  large-scale  randomized  controlled 
trials
4-6),  the  Third  Report  of  the  National  Cholesterol  Education 
Program  (NCEP)  Expert  Panel  on  Detection,  Evaluation,  and 
Tr e a t me n t  of  Hi gh Bl ood Ch ol e s t e r ol  i n Adu l t s  ( Adu l t  Tr e a t me nt  
Panel  III),  stated  that  diabetes  is  a  coronary  heart  disease 
equivalent
7). Thereafter, the American Diabetes Association (ADA) 
recommended  more  aggressive  pharmacological  therapy  in  the 
management  of  dyslipidemia  for  adults  with  diabetes.  The  LDL 
goal was set at <100 mg/dL. The ADA recommended that drug 
therapy  should  be  initiated  at  the  same  time  as  lifestyle 
intervention is started if the LDL-C level is 130 mg/dL or greater 
in  the  absence  of  coronary,  peripheral,  and  cerebral  vascular 
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mg/dL  or  greater  in  their  presence
8).  However,  among  patients 
treated with statins, the rate of achieving a reduced LDL-C goal 
after  16  weeks  of  treatment  was  65%  with  the  usual  dose  of 
atorvastatin,  but  only  19%  with  pravastatin
9, 10).  This  suggests 
that  a  more  practical  and  aggressive  strategy  for  rapidly  and 
effectively  reaching  a  given  treatment  goal  of  reduced  LDL-C 
l e v e l s  i s  u r g e n t l y  n e e d e d  f o r  p a t i e n t s  w i t h  d i a b e t e s .
So  far,  there  has  been  no  'gold  standard'  for  the  starting 
dose  and  dose  titration  of  a  statin  according  to  a  patient's 
L D L - C  l e v e l s ,  t o w a r d  t h e  e n d  o f  a c h i e v i n g  t h e  t a r g e t  l e v e l .  I f  
patients  were  started  on  a  dose  of  a  statin  by  anticipating  its 
effect  instead  of  relying  on  dose  escalation,  then  the  reduced 
LDL-C  target  might  be  reached  more  rapidly  and  effectively. 
Furthermore, appropriate dose adjustment of the statin based on 
L D L - C  l e v e l s  ma y  a l s o  b e  e s s e n t i a l  f o r  a c h i e v i n g  t h e  g o a l .  T h e  
cholesterol-lowering  effect  of  atorvastatin  usually  reaches  its 
maximum level at four weeks, with subsequent maintenance of a 
similar effect throughout the period of therapy
11). However, there 
are  no  clearly  established  guidelines  for  the  early  aggressive 
titration  of  statin  doses.
Besides the traditional risk factors for coronary heart disease, 
nontraditional  risk  factors  such  as  insulin  resistance,  endothelial 
dysfunction, impaired fibrinolysis evidenced by elevated levels of 
plasminogen  activator  inhibitor  type  1  (PAI-1),  low-grade  inflam-
mation  (hs-CRP  elevation),  microalbuminuria,  and  vascular  wall 
abnormalities  are  considered  to  be  contributors  to  the  excess 
risk  of  CHD  associated  with  diabetes,  which  cannot  be  fully 
explained  in  the  context  of  the  traditional  risk  factors  alone
12). 
Statins  also  provide  beneficial  effects  for  the  nontraditional  risk 
factors of CHD. These benefits include restoration of endothelial 
function,  stabilization  of  atherosclerotic  plaques,  and  decreases 
in  oxidative  stress  and  vascular  inflammation.  In  addition  to  its  lipid- 
lowering  effect,  atorvastatin  has  also  shown  an  anti-inflammatory 
effect associated with improved endothelial-dependent dilation in 
a  prospective  study
13, 14).
In this study, we first tested the effects of initial flexible doses 
and  early  aggressive  dose  titration  of  atorvastatin  according  to 
the  patient's  LDL-C  levels  as  a  practical  guideline  for  statin 
therapy.  Second,  we  measured  the  non-lipid-lowering  effects  of 
atorvastatin  in  the  same  patients,  based  on  flow-mediated 
endothelium-dependent  dilation  (FMD),  flow-mediated  endothelium- 
independent  dilation  (EID),  and  PAI-1  levels.
MATERIALS AND METHODS
Patients
Men and women aged 18-80 years were eligible for the study 
i f  t h e y  w e r e  h y p e r l i p i d e m i c  T 2 D M  p a t i e n t s  w i t h  L D L - C  l e v e l s ≥
130  mg/dL  or  glycated  hemoglobin  (HbA1c)  values  of  ≤  10% 
and triglyceride levels of ≤400 mg/dL at baseline. Patients were 
not included in this study if they had type 1 diabetes mellitus or 
serious medical illness, or if they had been treated with fibrates, 
corticosteroids,  azole-derivative  antifungal  agents,  or  niacin. 
Patients were also excluded if they were women of childbearing 
potential  not  using  contraception,  or  if  they  had  secondary 
causes  of  hyperlipoproteinemia  (thyroid-stimulating  hormone  ≥
1.5  times  the  upper  limit  of  normal,  blood  urea  nitrogen≥30 
mg/dL,  or  creatinine≥2.0  mg/dL  at  baseline),  uncontrolled 
hypertension  (sitting  systolic  blood  pressure  [BP]>160  mmHg, 
sitting  diastolic  BP>100  mmHg),  hepatic  disease,  or  impaired 
hepatic function (aspartate or alanine aminotransferase [AST/ALT] 
levels  >two  times  the  upper  limits  of  normal  at  baseline).  Other 
exclusion  criteria  were:  creatine  phosphokinase  (CPK)>three 
times the upper limit of the normal range at baseline, body mass 
index (BMI)>32 kg/m
2, a history of intolerance or hypersensitivity 
t o  H MG - C o A  r e d u c t a s e  i n h i b i t o r s ,  o r  a b u s e  o f  a l c o h o l  o r  o t h e r  
recreational  drugs.  Patients  with  cardiac  arrhythmia  were  not 
included  in  the  group  receiving  endothelial  function  measure-
ments.
Study  design
This  multicenter,  open-labeled,  prospective  study  was 
conducted  at  11  university-affiliated  diabetes  centers  in  Korea. 
Patients received appropriate doses of atorvastatin according to 
designed  criteria  for  a  total  of  eight  weeks.  Patients  who  were 
on  any  other  lipid-lowering  medications  before  enrollment 
underwent a  four-week washout period before being  placed  on 
the  standard  protocol.  The  patients  were  divided  into  three 
groups  according  to  their  initial  LDL-C  levels  (130-149  mg/dL, 
150-159  mg/dL,  and≥160  mg/dL),  and  10,  20,  and  40  mg  of 
atorvastatin  was  administered  as  an  initial  dose  in  each  group, 
respectively.
If the patient's LDL-C levels did not reduce to the target level 
after  four  weeks  of  treatment,  the  dose  was  increased  by  one 
step, up to 80 mg. If the LDL-C levels met the target after four 
weeks of treatment, the dose was maintained at the same level. 
All the patients were encouraged to adhere to their allocated diet 
or  exercise  therapy  during  the  entire  study  period.  The  study 
was conducted according to the principles of the Declaration of 
Helsinki;  it  was  approved  by  institutional  review  boards  at  all 
centers,  and  written  informed  consent  was  obtained  from  all 
patients.
Determination  of  sample  size 
The sample size was determined to be adequate to address 
the  study  hypothesis  that  atorvastatin  treatment  would  enable 
patients  to  achieve  their  designated  LDL-C  target  quickly,  with 
either no titration or just one titration step, provided the starting 
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by the patient's cardiovascular risk category. 151 patients were 
needed to make the study adhere to our assumed percentages: 
50%  of  patients  reaching  goal,  20%  dropouts,  and  a  lower 
bound  of  a  one-sided  95%  confidence  interval  with  a  width  of 
15% of the target population. However, we determined the final 
sample  size  of  198  patients  to  secure  adequate  patients. 
Assessments
Fasting  serum  lipid  profiles  in  all  centers,  and  endothelial 
function  and  PAI-1  level  measurements  in  three  centers,  were 
assessed  for  efficacy.  Patients  were  instructed  to  fast  for  12  h 
before each test, and they had no vigorous exercise or change 
in  diet  the  day  before  the  test.  Total  cholesterol  (TC)  and 
triglyceride  (TG)  levels  were  measured  enzymatically  after 
precipitation  of  the  other  lipoproteins.  The  LDL-C  level  was 
calculated  using  Friedewald's  equation  if  the  serum  triglyceride 
level was ≤400 mg/dL. The blood glucose level was measured 
using  an  automatic  enzymatic  method,  and  the  glycated 
hemoglobin  (HbA1c)  level  was  determined  by  high-performance 
liquid  chromatography  (HPLC;  Variant  II  HbA1c  analyzer; 
Bio-Rad,  Montreal,  Quebec,  Canada)  with  a  reference  range  of 
4.4～6.4%  of  total  hemoglobin.
Endothelial  function  was  assessed  at  baseline  and  at  week 
eight  by  echocardiography  with  monitoring  of  electrocardio-
grams,  which  measured  brachial  artery  flow-mediated  endothelium- 
dependent  dilation  (FMD)  and  brachial  artery  flow-mediated 
endothelium-independent  dilation  (EID).  Echocardiography  was 
performed  in  three  of  the  centers,  and  the  measurements  of 
FMD  and  EDI  by  recorded  images  were  performed  by  one 
investigator.  PAI-1  levels  were  measured  using  enzyme-linked 
immunosorbent (ELISA) kits (Biopool, Umea, Sweden) at baseline 
and  at  week  eight.  Physical  examinations,  measurements  of 
b l o o d  p r e s s u r e  a n d  b o d y  w e i g h t ,  a n d  l a b o r a t o r y  t e s t s  w e r e  
performed  at  every  visit,  and  any  adverse  event  (AE)  was 
recorded  for  safety  evaluation.
Outcome  measures
The  primary  efficacy  variable  was  the  percentage  of  patients 
achieving  their  National  Cholesterol  Education  Program  Expert 
Panel  on  Detection,  Evaluation,  and  Treatment  of  High  Blood 
Cholesterol  in  Adults,  Adult  Treatment  Panel  III  (NCEP  ATP  III) 
target  of  LDL-C<100  mg/dL  at  eight  weeks.  The  secondary 
efficacy  variables  included  the  percentage  changes,  from 
baseline  to  eight  weeks,  of  LDL-C,  HDL-C,  triglycerides,  total 
cholesterol,  non-HDL  cholesterol,  (LDL  cholesterol)/(HDL 
cholesterol)  ratio,  PAI-1,  FMD,  and  EID.
Statistical  analysis
All patients in the per protocol (PP) population were analyzed 
for  efficacy.  The  PP  population  consisted  of  patients  who  were 
assigned  to  a  starting  dose  of  atorvastatin,  who  had  both 
baseline  and  eight-week  LDL  cholesterol  efficacy  measure-
ments,  and  who  adhered  to  the  protocol  requirements.  For 
safety  analysis,  patients  who  had  at  least  one  medication  were 
included,  and  the  last-observation-carried-forward  (LOCF) 
approach  was  used  to  evaluate  missing  data.
Descriptive  statistics  such  as  mean,  standard  deviation, 
frequency,  and  percentage  have  been  used  to  present  the 
distributions  of  baseline  characteristics,  efficacy,  and  safety 
measurements. The primary efficacy variable was the percentage 
of  patients  achieving  their  LDL-C  NCEP  ATP  III  target  at  eight 
weeks.  The  overall  rate  of  achieving  the  target  LDL-C  95% 
confidence intervals (CI) are presented. The Chi-square test was 
used to compare the difference of rates among starting doses of 
atorvastatin.  The  baseline  characteristics  of  the  two  outcome 
groups (success or failure to achieve the target) were compared 
using  Satterthwaite  or  Student's  t-tests.
The secondary efficacy variables were the percentage changes 
from  baseline  to  eight  weeks  in  the  following  lipid  parameters: 
LDL cholesterol, HDL cholesterol, TG, TC, non-HDL cholesterol, 
(LDL cholesterol)/(HDL cholesterol) ratio, FMD, and EID; and the 
percent change from baseline to eight weeks in the PAI-1 level. 
Mean percentage changes from baseline in lipid parameters and 
PAI-1  were  compared  using  paired  t-tests.
W e  u s e d  S A S  v e r s i o n  8 . 0 1  f o r  s t a t i s t i c a l  a n a l y s i s ;  a l l  t e s t s  
were  two-sided  with  significance  assumed  at  p<0.05.
RESULTS
Patient  population
Of  322  subjects  screened,  evaluable  safety  data  were 
available for 209 patients. Among them, 149 patients completed 
this  study, and  all  the  analyzed  data  for  the  efficacy are  based 
on this group (Figure 1). The mean age was 58.4±8.5 y (range 
32-76  y),  and  106  (71.1%)  of  the  patients  were  women  (Table 
1). According to the initial LDL-C levels, 62 (41.6%), 18 (12.1%), 
and 69 (46.3%) of the 149 patients were assigned to receive 10, 
20,  and  40  mg  doses  of  atorvastatin,  respectively.
Efficacy
After  the  first  assessment  at  week  four,  9.7%  of  patients  in 
the  10  mg  group,  11.1%  of  patients  in  the  20  mg  group,  and 
8.7%  of  patients  in  the  40  mg  group  were  changed  to  higher 
doses. Thus, 56 (37.6%), 22 (14.8%), 65 (43.6%) and 6 (4%) of 
the 149 patients received 10, 20, 40, and 80 mg of atorvastatin, 
respectively,  starting  at  this  point  (Figure  2,  3).
At the end of the study in all dose groups, 89% of all patients 
achieved the target LDL-C level (95% CI, 84～94%). The target 
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Characteristic Mean±SD
Men  /  Women
Age  (yrs) 
Body  mass  index  (kg/m
2)
Diabetic  duration  (yrs)
HbA1c  (%)
Fasting  blood  glucose  (mg/dL) 
History  of  antihyperlipidemic  agents 
( Y e s  /  N o )
Height  (cm)
Weight  (kg)
LDL-C  level  (mg/dL)
43  (28.9%)  /  106  (71.1%)
58.4±8.5
24.8±2.7
7.9±7.0
7.5±1.1
147.8±42.7
15  (10.1%)  /  134  (89.9%)
159.4±8.0
63.3±9.2
160.3±22.4
Table  1.  Baseline  characteristics  of  subjects  (n=149) 
Group 
Number 
(achieved/total)   Achieving  Rate
†
10  mg
20  mg
40  mg
80  mg
49  /  56
19  /  22
61  /  65
 4  /  6
87.5%
86.4%
93.9%
66.7%
  Total   149 89.3%
†Chi-square  test  p=0.1722  (95%  confidence  interval  84.3～94.2) 
Table 2. Percentage of patients achieving NCEP‐LDL cholesterol goal at
week  8  (n=149)
Figure  2.  Progress  of  the  study  according  to  atorvastatin  dosage  adjustment.
Figure  1.  Patient  population  and  study  protocol.  Among  the  322 
patients  screened,  149  completed  the  protocol.
in the 40 mg group, 86.4% in the 20 mg group, and 87.5% in 
the  10  mg  group  (Table  2).
Serum  parameters  from  baseline  to  eight  weeks  were 
significantly  lowered  for  LDL-C  (-51.2±15.6%),  TC  (-38.0± 
11.9%),  TG  (-21.6±42.0%),  and  non-HDL-C  (-47.1±13.6%) 
(Figure  4).  Among  the  lipid  parameters,  LDL-C,  TC,  and 
non-HDL-C values were significantly decreased after eight weeks 
compared  with  baseline  levels,  in  a  dose-dependent  manner 
(p<0.0001). Atorvastatin was more effective in lowering TG in the 
20 mg group and inducing greater change in LDL-C/HDL-C ratio 
in  the  40  mg  group  than  the  other  groups,  but  there  were  no 
statistically  significant  differences  among  groups,  respectively 
(p=0.2128,  p=0.9875).  Interestingly,  the  HDL-C  level  of  the  40 
mg  group  was  significantly  lowered  compared  with  the  10  mg 
and  20  mg  groups  (p=0.0079).Characteristic
Success
(N=133)
Failure
(N=16)
Satterthwaite  or  t-test
Age  (yrs)
BMI  (kg/m
2)
Diabetic  duration  (yrs)
LDL-C  (mg/dL)
    Baseline
    End  point  (8  week)
Insulin  (IU/mL)
Hemoglobin  A1c  (%)
    Baseline
58.5±8.5
24.9±2.7
8.2±7.2
160.3±21.8
71.3±14.9
7.7±8.0
7.6±1.2
58.1±8.8
24.5±2.5
5.6±4.0
160.1±27.2
123.0±22.9
10.8±18.4
7.2±1.0
p=0.8833
p=0.5414
p=0.0333
*
p=0.9791
P<0.0001
p=0.5320
p=0.2401
Table  3.  Characteristics  of  each  covariate  in  success  or  failure  group  (N=149)
Figure  3.  Dosage  titration  according  to  1
st L D L - C  t a r g e t  a t  w e e k  4  
(n=149). After 4 weeks, 9.7% of patients in the 10 mg group, 11.1% of 
patients in the 20 mg group, and 8.7% of patients in the 40 mg group 
were  changed  to  higher  doses.
Figure  5.  Flow-mediated endothelium-dependent dilation over time. Data
are  means±SD.  *p<0.05  vs.  before  treatment.
Figure  4.  Mean  percent  change  of  lipid  parameters 
from baseline after 8 weeks (n=149). Black bar, 10 mg; 
shaded  bar,  20  mg;  white  bar,  40  mg. 
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Subgroup  analysis  (success  vs.  failure  groups)
The rates of patients achieving their target did not show any 
significant  differences  in  relation  to  covariates  (Table  3).  Of t h e  
149  total  patients,  135  (90.6%)  reached  the  target  level  of 
LDL-C  at  four  weeks,  but  12  (8%)  of  these  patients  had 
elevated  LDL-C  levels  (>100  mg/dL)  at  eight  weeks.  Fourteen 
patients needed to increase their dosage at four weeks because 
they  did  not  reach  the  target  at  four  weeks  ('failure').  The 
success and failure groups did not differ significantly in age, BMI, 
b a s e l i n e  L D L - C  i n s u l i n ,  o r  H b A 1 c  l e v e l s ,  b u t  d i d  s h o w  
differences  in  the  duration  of  diabetes  (success  vs.  failure, 
8.2±7.2  vs.  5.6±4.0  years,  p<0.05)  (Table  3).
Endothelial  function  measurements
The baseline clinical characteristics of the endothelial function 
study  subpopulation  are  listed  in  Table  4.  Atorvastatin 
supplementation  improved  FMD  after  eight  weeks  of  treatment 
(Figure 5), but EID was not significantly affected. PAI-1 tended to 
decrease  in  patients  receiving  atorvastatin,  but  this  parameter 
change  did  not  reach  statistical  significance.
Safety
Among  the  209  original  study  subjects,  30  patients  treated 
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Week  0 Week  8 %  change p v a l u e
FMD  (%)
8.3±4.0
(1.4～17.9)
11.0±4.1
(1.8～21.1)
46.4±52.0
**
(-23.0～200)
0.0001
EID  (%)
15.5±5.4
(5.7～28.9)
15.9±5.2
(6.1～28.1)
4.3±14.7
(-36.9～36.0)
0.0714
PAI-1  (IU/mL)
27.1±10.2
(9.8～51.6)
25.1±12.2
(4.6～52.0)
-0.2±46.0
(-78.5～113.1)
0.9733
D a t a  a r e  m e a n s ± S D  ( r a n g e ) .
FMD,  flow-mediated  endothelium-dependent  dilation;  EID  (flow‐mediated  endothelium-independent  dilation);  PAI-1,  plasminogen  activator 
inhibitor-1. 
Table  4.  Pre-and  post-treatment  values  and  percentage  changes  of  FMD,  EID,  and  PAI-1
Number  (%)
Subjects  analyzed  for  safety
Subjects  with  adverse  events
Subjects  with  drug‐related  adverse  events
Subjects  withdrawn  due  to  drug‐related  adverse  events
1)
Subjects  withdrawn  due  to  drug‐related  laboratory  adverse  events
2)
209  (100)
30  (14.4)
24  (11.5)
7  (3.3)
3  (1.4)
Case  of  adverse  events  (>  1%)
Abdominal  pain
ALT  increase
Dizziness
Headache/  Dyspepsia
Creatine  phosphokinase  increase
Number 
6
5
4
3
3
Percent
2.9
2.4
1.9
1.4
1.4
1)Erythematous  rash,  pruritus,  rash,  abdominal  pain,  dizziness,  dyspnea
2)AST/ALT  increase,  abnormal  urine  analysis,  phosphatase  alkaline  increase,  creatine  phosphokinase  increase 
Table  5.  Summary  of  safety  analysis
patients (12%) reported adverse events that were considered by 
the investigators to be possibly, probably, or definitely associated 
with  treatment.  Most  of  these  events  were  mild  to  moderate  in 
intensity.  The  rate  of  adverse  events  increased  with  increasing 
d r u g  d o s a g e  ( 1 0 % ,  1 4 % ,  a n d  1 8 %  i n  t h e  1 0 ,  2 0 ,  a n d  4 0 m g  
groups,  respectively.  p=0.3783).  The  most  commonly  reported 
events  were  abdominal  pain,  dizziness,  headache,  and 
dyspepsia.  Ten  patients  (4.7%)  withdrew  because  of  these 
adverse events. Two patients discontinued the drug because of 
elevation  of  their  ALT  levels  (from  18  to  208  IU/L  and  from  18 
to  178  IU/L  after  four  weeks  of  treatment)  and  one  of  them 
because  of  an  elevation  of  CPK  level  (from  97  to  346  IU/L). 
There  were  no  cases  of  persistent  elevations  in  serum 
transaminases  (greater  than  three  times  the  upper  limit  of 
normal)  or  reports  of  myopathy  in  any  treatment  group.  No 
serious  adverse  event  was  reported  (Table  5).
DISCUSSION
In  this  study,  we  aimed  to  develop  an  intensive  treatment 
guideline for lipid-lowering therapy that would achieve an LDL-C 
target  in  T2DM  patients  rapidly  and  effectively.  We  therefore 
observed  the  rate  of  achieving  the  NCEP  treatment  goal  within 
eight  weeks  of  atorvastatin  therapy,  with  the  starting  dose 
stratified  according  to  the  individual  patient's  baseline  LDL-C 
l e v e l .  A t o r v a s t a t i n ,  a d m i n i s t e r e d  a t  1 0 ,  2 0 ,  4 0 ,  a n d  8 0  m g ,  
produced  effective  reductions  in  total  cholesterol  and  LDL-C 
within  eight  weeks.
Many  primary  and  secondary  prevention  studies  provide 
s t r o n g  s u p p o r t  f o r  t h e  u s e  o f  m o d e r a t e  d o s e s  o f  s t a t i n s  i n  
patients  with  diabetes.  Although  the  NCEP  and  ADA  guideline 
for the LDL-C target  is  100 mg/dL,  only a  few  studies  support 
the  idea  that  lower  LDL-C  levels  lead  to  better  cardiovascular 
outcome.  The  Heart  Protection  Study  (HPS),  which  had  the 
largest  diabetes  subgroup,  demonstrated  a  consistent  (close  to 
2 5 % )  r e d u c t i o n  a n d  a  5 ～ 7 %  a b s o l u t e  r i s k  r e d u c t i o n  i n  
cardiovascular  events  with  statin  therapy  regardless  of  initial 
LDL-C levelseven among patients whose initial levels were below 
t h e  N C E P  t a r g e t  o f  1 0 0  m g / d L
15).  For  better  cardiovascular 
outcome, aggressive therapy with statins is warranted in diabetic 
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m e d i c a t i o n s  i n  l o w e r i n g  L D L - C  i s  v a r i a b l e .  M o s t  s t a t i n s  a r e  
c a p a b l e  o f  a c h i e v i n g  t h e  L D L - C  g o a l  i n  s u b j e c t s  w i t h  L D L - C  
l e v e l s  o f  l e s s  t h a n  1 7 0  m g / d L .  A t o r v a s t a t i n  a t  4 0  m g  o r  
simvastatin  at  80  mg  could  achieve  the  goal  in  subjects  with 
LDL-C levels of 170-189 mg/dL, but only atorvastatin at 80 mg 
and  the  recently  developed  drug  rosuvastatin  could  do  so  for 
subjects  with  LDL-C  levels≥190  mg/dL
16).  To  achieve  the 
d e s i r e d  t a r g e t  o f  1 0 0  m g / d L ,  d o s e  a d j u s t m e n t  w o u l d  i n e v i t a b l y  
be needed in subjects with higher LDL-C levels. Considering the 
time and cost efficacy, starting-dose stratification seemed to be 
a  valuable  method  in  daily  clinical  practice  and  was  eventually 
reveal ed t o be so i n t hi s  st udy, as  shown by t he LDL- C t ar get  
achievement  rate  of  89%  at  eight  weeks.  Furthermore,  most  of 
the LDL-C reduction was achieved within four weeks. The clinical 
characteristics  of  subjects  who  achieved  the  target  level  were 
not different from those of who did not achieve it, except for the 
overall  duration  of  diabetes  mellitus.  However,  because  most 
patients  achieved  the  target level,  the 'failure'  group  was  small. 
If  more  subjects  had  been  studied,  differences  between  the 
success  and  failure  groups  might  have  been  more  clearly 
defined.
The  mean  percentages  of  LDL-C,  total  cholesterol,  and 
non-HDL  cholesterol  were  all  reduced  in  a  dose-dependent 
manner  from  baseline.  The  mean  LDL-C  changes  were  higher 
than  the  CURVES  study  achieved  with  initial  dose  randomiza-
tion
17).  Initial  dose  stratification  could  explain  the  differences  in 
the  effectiveness  of  the  same  dosage  of  the  same  drug. 
Moreover, the HDL cholesterol level was slightly increased in the 
10 mg and 20 mg groups, and decreased in the 40 mg group, 
after eight weeks of treatment. The degree of TG decrease was 
a l s o  s m a l l e r  i n  t h e  4 0  m g  g r o u p  t h a n  i n  t h e  2 0  m g  g r o u p ,  
although  this  was  not  statistically  significant.
Endothelial  dysfunction  occurs  early  in  the  atherosclerotic 
process  and  is  associated  with  other  cardiovascular  risk 
factors
18);  impairment  of  fibrinolytic  activity  has  been  reported  in 
dysmetabolic conditions associated with atherosclerosis, such as 
diabetes mellitus, and is related to endothelial function
19). Recent 
studies  have  suggested  that  statins  might  have  pleiotropic 
effects  on endothelial function beyond  their lipid-lowering  effect. 
Several mechanisms by which statins might improve endothelial 
function,  including  increasing  the  synthesis  of  nitric  oxide, 
decreasing  the  synthesis  of  endothelin-1,  and  inhibiting  LDL- 
cholesterol oxidation, have been suggested
20-22). We showed that 
treatment with atorvastatin for eight weeks significantly improved 
endothelial function in patients with type 2 diabetes. Atorvastatin 
also  reduced  the  PAI-1  levels,  but  the  effect  failed  to  reach 
statistical  significance,  probably  because  the  study  was  short 
and patients showed considerable variation in their PAI-1 levels. 
Although  further  studies  are  needed  to  elucidate  the 
mechanisms,  these  results  suggest  that  early  treatment  with 
atorvastatin  could  reduce  the  incidence  of  coronary  heart 
disease  in  patients  with  diabetes.
A  few  adverse  events  were  reported  in  this  study.  Ten 
patients withdrew because of drug-related events. Among them, 
three  showed  drug-related  adverse  biochemical  changes 
(elevations  in  ALT  or  CPK  levels),  which  were  reversible  after 
drug  discontinuation.  Thus,  atorvastatin  appears  to  be  relatively 
safe  for  the  treatment  of  patients  with  T2DM,  even  at  high 
doses.
In conclusion,  an initial flexible dose  of  atorvastatin treatment 
based  on  initial  LDL-C  levels  can  achieve  a  target  LDL-C  level 
effectively,  rapidly,  and  safely  in  most  hyperlipidemic  patients 
with  T2DM.  Therefore,  this  dose-escalation  schedule  might  be 
helpful,  especially  for  high-risk  patients  seen  in  daily  clinical 
practice. However, the clinical significance remains to be clarified 
by  future  studies.
Appendix
Participants  of  the  Atorvastatin  Study  Group  in  Korea  are  as 
follows:  H.Y.  Son,  K.H.  Yoon,  Y.H.  Choi,  H.S.  Kwon,  S.H.  Ko, 
Department  of  Internal  Medicine;  The  Catholic  University  of 
Korea;  I.K.  Lee,  H.S.  Kim,  K.K.  Park,  M.J.  Kim,  Department  of 
Internal Medicine, The Keimyung University, School of Medicine; 
J.T. Woo, Y.S. Kim, Department of Internal Medicine, Kyung Hee 
University College of Medicine; D.S. Choi, Department of Internal 
Medicine, Korea University College of Medicine; M. K. Lee, H.J. 
Kim, Department of Internal Medicine, SungKyunKwan University 
S c h o o l  o f  M e d i c i n e ;  K .  S .  P a r k ,  H .  K .  L e e ,  S e o u l  N a t i o n a l  
University College of Medicine; J. Y. Park, E. H. Koh, University 
of  Ulsan  College  of  Medicine;  H.  C.  Lee,  B.  S.  Cha,  Yonsei 
U n i v e r s i t y  C o l l e g e  o f  M e d i c i n e ;  M .  Y .  C h u n g ,  D .  H .  C h o ,  
Chonnam  National  University  College  of  Medicine;  Y.  K.  Kim,  I. 
J. Kim, Pusan National University College of Medicine; Y. K. Kim, 
B.  J.  Ku,  Chungnam  National  University  College  of  Medicine. 
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